携手共赢丨中山大学肿瘤防治中心张力教授团队-中国肺癌原创临床研究阶段汇总 / 开普饭

Lancet Oncol

Lancet Oncol Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial Li Zhang (2012)

Lancet Oncol

Lancet Oncol Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial Li Zhang (2013)

Onco Targets Ther

Onco Targets Ther Randomized double-blind trial of prophylactic topical Evozac® Calming Skin Spray for gefitinib-associated acne-like eruption Li Zhang (2014)

Sci Rep

Sci Rep QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC Li Zhang (2015)

Sci Rep

Sci Rep Randomized, multicenter study of gefitinib dose-escalation in advanced non-small-cell lung cancer patients achieved stable disease after one-month gefitinib treatment Li Zhang (2015)

J Thorac Oncol

J Thorac Oncol Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804) Li Zhang (2015)

Medicine

Medicine Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung（C-TONG 0807）：an open-label，single arm，multicenter phase II study Li Zhang (2015)

J Thorac Oncol

J Thorac Oncol First-in-human phase I study of AC0010, a mutant-selective EGFR Inhibitor in non-small cell lung cancer: safety, efficacy, and potential mechanism of resistance Li Zhang (2018)

Lung Cancer

Lung Cancer Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial Li Zhang (2018)

J Clin Pharmacol

J Clin Pharmacol Pharmacokinetics of osimertinib in Chinese patients with advanced NSCLC: A phase 1 study Li Zhang (2018)

Oncologist

Oncologist KEYNOTE-032: A randomized phase I study of Pembrolizumab in Chinese patients with advanced non-small-cell lung cancer Li Zhang (2020)

Clin Transl Med

Clin Transl Med Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer Li Zhang (2019)

Lancet Respir Med

Lancet Respir Med Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial Li Zhang (2019)

Lancet Respir Med

Lancet Respir Med Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study Li Zhang (2019)

Transl Lung Cancer Res

Transl Lung Cancer Res Biosimilar candidate IBI305 pluspaclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer Li Zhang (2020)

J Thorac Oncol

J Thorac Oncol Efficacy and safety of Sintilimab plus Pemetrexed and Platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized, double-blind, phase 3 study (Oncology pRogram by Innov ENT anti-PD-1-11) Li Zhang (2020)

J Thorac Oncol

J Thorac Oncol Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706) Li Zhang (2021)

J Thorac Oncol

J Thorac Oncol Decoding the evolutionary response to Ensartinib in ALK-positive non-small-cell lung cancer patients by dynamic circulating tumor DNA sequencing Li Zhang (2021)

Ann Transl Med

Ann Transl Med Docetaxel maintenance therapy versus best supportive care after first-line chemotherapy with different dose docetaxel plus cisplatin for advanced non-small cell lung cancer (TFINE study, CTONG-0904): an open-label, randomized, phase III trial Li Zhang (2021)

J Thorac Oncol

J Thorac Oncol Update overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic non-squamous NSCLC in the phase III ORIENT-11 study Li Zhang (2021)

Oncologist

Oncologist A phase I dose escalation study of the safety, tolerability, and pharmacokinetics of Ipilimumab in Chinese patients with select advanced solid tumors Li Zhang (2021)

附鼻咽癌部分

J Clin Oncol

J Clin Oncol Phase III study comparing standard radiotherapy with or without weekly Oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: Preliminary results Li Zhang (2005)

Cancer Chemother Pharmacol

Cancer Chemother Pharmacol Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy Li Zhang (2008)

Eur J Cancer

Eur J Cancer Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastase Li Zhang (2011)

Oral Oncol

Oral Oncol A randomized trial of induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus radiotherapy for locoregionally advanced nasopharyngeal carcinoma Li Zhang (2012)

Cancer Chemother Pharmacol

Cancer Chemother Pharmacol Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy Li Zhang (2012)

Lancet

Lancet Gemcitabine plus cisplatin versus fluorouracilplus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial Li Zhang (2016)

BMC Cancer

BMC Cancer Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as treatment for metastatic nasopharyngeal carcinoma Li Zhang (2016)

Lancet Oncol

Lancet Oncol Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials Li Zhang (2018)

Oncologist

Oncologist A phase I/II open-label study of Nivolumab in previously treated advanced or recurrent nasopharyngeal carcinoma and other solid tumors Li Zhang (2019)

Lancet Oncol

Lancet Oncol Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyneal carcinoma （CAPTAIN-1s）：a multicentre，randomised，double-blind，phase 3 trial Li Zhang (2021)

J Clin Oncol

J Clin Oncol Gemcitable plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma：Final overall survival analysis of GEM20110714 phase III study Li Zhang (2021)